This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier’s archiving and manuscript policies are encouraged to visit:

http://www.elsevier.com/copyright
Do Lasers or Topicals Really Work for Nonmelanoma Skin Cancers?
Lori Brightman, MD,* Melanie Warycha, MD, † Robert Anolik, MD,* and Roy Geronemus, MD*

Novel strategies are urgently needed to address the millions of nonmelanoma skin cancers treated in the United States annually. The need is greatest for those patients who are poor surgical candidates or those prone to numerous nonmelanoma skin cancers and therefore at risk for marked disfigurement. Traditional treatment strategies include electrosurgery with curettage, radiation therapy, cryotherapy, excision, and Mohs micrographic surgery. Alternatives to traditional treatment, including topical medications and light or laser therapies, are becoming popular; however, there are various degrees of efficacy among these alternative tactics. These alternatives include topical retinoids, peels, 5-fluorouracil, imiquimod, photodynamic therapy, and lasers. The purpose of this paper is to review the available data regarding these alternative strategies and permit the reader to have a sense of which therapies are reasonable options for care.

Semin Cutan Med Surg 30:14-25 © 2011 Elsevier Inc. All rights reserved.

It has been well documented that the incidence of nonmelanoma skin cancer (NMSC) is increasing, of which approximately 75% of cases each year are attributed to basal cell carcinomas (BCCs) and 20% to squamous cell carcinomas (SCCs). On the basis of an analysis of the Medicare Total Claims Data Set and the National Ambulatory Medical Care Survey for the years 1992 and 1996-2006, the total number of NMSCs treated in the United States in 2006 was more than 2.1 million. Furthermore, there was a 14.3% increase in the number of persons with at least one procedure for NMSC from 2002 to 2006.1 The rates in immunosuppressed populations are even greater, with retrospective studies documenting skin cancer development in 13% to 52% of transplant recipients, with incidence increasing with years of immunosuppression.2-5 The precipitous increase in NMSCs, especially in younger patient populations, could translate into an alarming number of NMSCs as the population ages. This progressive increase in the number of NMSCs highlights the need for multiple treatment options in addition to traditional surgical approaches.

According to data from the Medicare Current Beneficiary Study from 1992 to 1995, the total cost of nonmelanoma skin cancer management was estimated to be $426 million per year.6 If estimating costs for the general population, treatment of NMSCs has exceeded more than one billion dollars per year.7 This financial burden underlies the need for prevention education in addition to more economical treatment strategies.

Standard Treatment Modalities for Nonmelanoma Skin Cancer

Both surgical and nonsurgical treatment modalities for NMSC have been developed, with the common goal of achieving a high cure rate with minimal tissue destruction and an acceptable cosmetic result. Mohs micrographic surgery is considered the gold standard for the treatment of nonmelanoma skin cancer because it allows for the histologic assessment of peripheral and deep margins and has a 5-year recurrence rate of 1%-3.2% for primary basal cell cancer (up to 6.7% for recurrent BCCs) and 3%-5.9% for SCCs.8 This is in comparison with standard excision, with a recurrence rate of 5.3%-10.1% for BCCs (primary and recurrent) and up to 8% for SCCs.9-11 Although cure rates with cryosurgery and electrodesiccation and curettage approach those of surgical excision, these techniques have an increased risk of pigment alteration and either hypertrophic or atrophic scarring.

Although the surgical approach for NMSC has rather low recurrence rates and is considered standard of care for many nonmelanoma skin cancers, there are circumstances in which...
surgical alternatives are needed and a less invasive option is appropriate. Newer nonsurgical treatment modalities, including the use of topical pharmacotherapy, such as tazarotene, 5-fluorouracil (5-FU) and imiquimod, photodynamic therapy (PDT), and laser or light treatment will be the subject of this review.

Role of Alternative Treatment Modalities for Nonmelanoma Skin Cancer

There are many factors that need to be considered in selecting the most appropriate treatment modality in patients with NMSC. Patients deemed to be poor surgical candidates, patients those with NMSC imposing upon critical anatomical structures, or those in whom cumulative surgical procedures for diffuse disease will result in functional or cosmetic disfigurement (ie, patients with basal cell nevus syndrome) may benefit from noninvasive treatment options. Furthermore, the size of the lesion or the presence of multiple adjacent lesions could also be an indication for nonsurgical approaches as primary tumor treatment or as adjunct to reduce tumor burden. Patients may also prefer the ease of application of a topical regimen compared with surgery. Finally, the location of a lesion in an area of poor wound healing or in a cosmetically sensitive area may necessitate treatment with nonsurgical modalities.12,13

Review of Topical Treatment Regimens for Nonmelanoma Skin Cancer

Tazarotene
The topical retinoid tazarotene has been theorized to mitigate the growth of tumor cells. A few small trials to date have examined its efficacy in the treatment of NMSC. Peris et al18 examined once daily application of tazarotene, 0.1% gel for 5–8 months in the treatment of BCCs and noted a 53% clearance rate, in addition to a 47% reduction in size for residual tumors. A larger randomized phase 2 trial sponsored by the National Cancer Institute to investigate topical tazarotene in the treatment of BCCs is currently ongoing. Treatment of SCC in situ (SCCIS) with topical tazarotene, 0.1% gel has also been investigated, with daily application for 6 months resulting in a 47% clearance rate in a study cohort of 15 patients. Of note, more than 30% of patients withdrew from this study because of adverse effects.15

Fluorouracil for Basal Cell Carcinoma
Topical 5-FU is approved by the Food and Drug Administration for the treatment of actinic keratoses and superficial BCCs. This chemotherapeutic agent inhibits thymidylate synthetase, thereby disrupting DNA synthesis in actively proliferating cells. Despite its treatment indications, there are surprisingly few studies evaluating the efficacy of 5-FU in the treatment of BCCs. In fact, in older studies, authors discuss formulations of 5-FU that are not readily available, thus questioning the applicability of these data.16 As such, Gross et al17 set out to reevaluate the efficacy of 5-FU in BCCs in 2007 in an open-label study of twice-daily application of 5-FU for up to 12 weeks in 29 patients with 31 biopsy-proven superficial BCCs. With a mean treatment duration of 10.5 weeks, 28 of 31 (90%) lesions exhibited complete clearance upon surgical excision with good cosmetic outcome, thus substantiating prior results regarding the efficacy and tolerability of 5-FU in the treatment of superficial BCCs.

Fluorouracil for Squamous Cell Carcinoma In-Situ
Although the use of 5-FU has also demonstrated efficacy in the treatment of SCCIS, most of the data stems from case reports and open-label studies rather than randomized controlled trials. In a study by Bargman et al,18 the twice-daily application of 5-FU for up to 9 weeks, with repeat courses at the discretion of the treating physician, was evaluated in 24 patients with 26 cases of histologically proven SCCIS. Post-treatment biopsies were performed (time of biopsy not disclosed) in 18 of 26 lesions, 2 of which revealed residual SCCIS. Of the remaining lesions, 6 had clinically resolved and were not biopsied, and 2 were lost to follow-up, with the average duration of clinical follow-up noted to be 55.2 months. By using a dosing regimen of 5-FU daily for 1 week followed by twice daily for 3 weeks for 1 to 2 cycles, Salim et al19 demonstrated a complete clinical clearance in 22 of 33 (67%) cases of SCCIS at 6-weeks follow-up. This was in comparison with an 88% clinical response after photodynamic therapy. At 1-year follow-up, 6 recurrences were documented in the 5-FU treatment group, thus lowering the overall response rate to 48%.

A similar dosing scheme was evaluated by Morton et al20 in 2006 in which treatment of SCCIS with 5-FU (once daily for 1 week then twice daily for 3 weeks, up to 2 cycles) or cryotherapy (minimum freeze time of 20 s) was compared with 2 cycles of photodynamic therapy with methyl aminolevulinate (prior curettage, incubation for 3 hours, red light 570-670 nm, 75 J/cm²). At 1 year posttreatment, the clinical complete response rate with 5-FU was 69% (20/29) on the basis of a per-protocol analysis, compared with an 80% response with methyl-aminolevulinate (MAL)-PDT and 67% response rate with cryotherapy. Thus, on the basis of available data, the response of SCCIS to treatment with 5-FU is poor, with a 48%-69% clearance rate at 1 year on the basis of a treatment regimen of once daily application for 1 week followed by twice daily application for 3 weeks.

Imiquimod for Basal Cell Carcinoma
Imiquimod, 5% cream (Aldara; Graceway Pharmaceuticals, Malvern, PA) was first approved by the Food and Drug Administration in 1997 for the topical treatment of external genital and perianal warts, and later for actinic keratoses and in 2004 for superficial BCCs. Imiquimod functions as an immune response modifier that binds to toll-like receptor 7 and induces transcription of interferon-α, interferon-γ, and
tumor necrosis factor-α, thus stimulating both innate and acquired immunity. A new formulation of imiquimod, 3.75% cream (Zyclara; Graceway Pharmaceuticals, LLC, Bristol, TN) is also approved for the treatment of actinic keratoses on the face and scalp, although this concentration has yet to be studied in nonmelanoma skin cancer.

A number of randomized controlled trials have been conducted to assess the efficacy of imiquimod, 5% cream in the treatment of superficial BCCs. A variety of dosing regimens and treatment durations have been evaluated, with a reported histopathologic clearance rate between 79% and 100% for a once-daily application regimen and 81%-82% for a 5-days-per-week application regimen. A summary is provided in Table 1.

In a small randomized, double-blind pilot study by Beutner et al., in 35 patients with superficial or nodular BCC, various imiquimod dosing regimens were examined with a treatment duration of up to 16 weeks. Surgical excision and histopathologic analysis were performed at 6 weeks after treatment completion. Patients who were randomized to twice-daily (n = 7), once-daily (n = 4), and 3 times per week (n = 4) application of imiquimod had complete histologic clearance of target tumors compared with a 9% response rate in the vehicle control group. Those patients randomized to twice weekly (n = 5) and once weekly (n = 4) experienced lower efficacy rates.

Schulze et al. conducted a randomized, vehicle-controlled, double-blind study of 166 patients evaluating the daily application of imiquimod, 5% cream to superficial BCCs for a treatment duration of 6 weeks. Analyzing the intent-to-treat dataset, the composite clearance rate was 77% for the imiquimod group and 6% for the vehicle control group (P < 0.001). Histopathological clearance was 80% for the imiquimod group and 6% for the vehicle control group (P < 0.001). Approximately 30% of patients in the imiquimod treatment group experienced local skin reactions (erythema, erosions, and scabbing/crusting) versus 1% in the vehicle control group.

Various dosing regimens for the treatment of superficial BCCs with imiquimod, 5% cream were investigated by Geisse et al. in a randomized, double-blind, vehicle-controlled study published in 2002. The findings in this study indicated that efficacy was highest for the twice daily dosing regimen with 100% histopathologic clearance after 12 weeks of application with excisions performed 6 weeks posttreatment; however, severe local skin reactions were documented in 3/10 patients, including erythema and scabbing. The complete response rate for once daily application for 12 weeks was 87.1% (27/31) and 80.8% (21/26) for 5 days per week application for 12 weeks. The authors of this study concluded that the once daily and 5 days per week regimen had the most acceptable clearance rates and safety profile.

Similarly, 2 imiquimod dosing regimens for the treatment of superficial BCCs, including a 5-day per week application for 6 weeks (vehicle vs imiquimod) and daily application for 6 weeks (vehicle vs imiquimod) were compared by combining the data from 2 separate, multicenter, randomized, double-blind, vehicle-controlled studies. Lesions were examined

<table>
<thead>
<tr>
<th>Sample Size</th>
<th>Dosing Regimen</th>
<th>Treatment Duration, wks</th>
<th>Time of Histologic Assessment, wks</th>
<th>Clearance Rate, %*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superficial BCC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geisse et al</td>
<td>Twice a day</td>
<td>12</td>
<td>6</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Daily</td>
<td>12</td>
<td>6</td>
<td>87.1</td>
</tr>
<tr>
<td></td>
<td>Daily 5 times/wk</td>
<td>12</td>
<td>6</td>
<td>80.8</td>
</tr>
<tr>
<td></td>
<td>Daily 3 times/wk</td>
<td>12</td>
<td>6</td>
<td>51.7</td>
</tr>
<tr>
<td>Geisse et al 2004</td>
<td>Daily</td>
<td>6</td>
<td>12</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>Daily 5 times/wk</td>
<td>6</td>
<td>12</td>
<td>82</td>
</tr>
<tr>
<td>Marks et al</td>
<td>Twice a day</td>
<td>6</td>
<td>6</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>Daily</td>
<td>6</td>
<td>6</td>
<td>87.9</td>
</tr>
<tr>
<td></td>
<td>Twice daily 3 times/wk</td>
<td>6</td>
<td>6</td>
<td>73.3</td>
</tr>
<tr>
<td></td>
<td>Daily 3 times/wk</td>
<td>6</td>
<td>6</td>
<td>69.7</td>
</tr>
<tr>
<td>Schulze et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daily</td>
<td>6</td>
<td>12</td>
<td>80</td>
</tr>
</tbody>
</table>

| Nodular BCC |
| Eigentler, et al | Daily 3 times/wk      | 8                       | 8                                | 64†               |
|            | Daily 3 times/wk      | 12                      | 8                                | 63†               |
| Huber, et al | Daily 3 times/wk      | 12                      | 12                               | 100               |
| Shumack, et al | Daily                | 12                      | 6                                | 76                |
|            | Daily 5 times/wk      | 12                      | 6                                | 70                |
|            | Daily 3 times/wk      | 12                      | 6                                | 60                |
|            | Daily                 | 6                       | 6                                | 71                |
|            | Twice daily 3 times/wk| 6                       | 6                                | 42                |
|            | Daily 3 times/wk      | 6                       | 6                                | 59                |

BCC, basal cell carcinoma.

*Based on histologic clearance.
†Not based on intent-to-treat analysis.
and excised at 12 weeks posttreatment. When an intent-to-treat analysis was undertaken, a statistically significant difference in complete clearance was not seen between the 5 days per week application group (82% histologic clearance, 152/185) and daily application group (79% histologic clearance, 141/179). A greater rate of application site reactions was appreciated, however, with daily application of imiquimod compared with the 5-day per week application (P = 0.002). The most commonly reported reactions included itching (26% in daily application group compared with 16% in 5 days per week application group), burning (9% in daily application group compared with 6% in 5 days per week application group), and pain (6% in daily application group and 3% in 5 times per week application group).24

Marks et al25 likewise published a randomized, open-label study evaluating imiquimod application twice daily, once daily, twice daily 3 times per week, and once daily 3 times per week in 99 patients with superficial BCC for a total treatment duration of 6 weeks. Histologic assessment was conducted at 6 weeks posttreatment. When an intent-to-treat analysis was undertaken, a complete response rate of 100% (3/3) was reported in the twice daily application group, compared with 87.9% (29/33) in the once daily application group. This rate dropped to 73.3% (22/30) for patients in the twice daily 3 times per week group and to 69.7% (23/33) in the once daily 3 times per week group. Enrollment in the twice daily application group was limited secondary to reports of application site skin reactions.

Regarding the efficacy of imiquimod in the treatment of nodular BCCs, few randomized controlled trials have been published to date. In general, lower clearance rates have been demonstrated after treatment with imiquimod in cases of nodular BCC given the depth of tumor infiltration. Shumack et al26 published the results of 2 multicenter studies, including a 6 week randomized open-label study and a 12 week randomized, vehicle-controlled, double-blind study evaluating 4 dosing regimens of imiquimod, with histologic assessment conducted at 6 weeks posttreatment. In this study, the highest efficacy was seen with daily application of imiquimod for 12 weeks (76% clearance rate, 16/21), although this was similar to the clearance rate seen with daily application of imiquimod for 6 weeks (71% clearance rate, 25/35). Four patients discontinued treatment because of local skin reactions in the once daily application group. Of note, a twice daily dosing scheme was attempted; however, enrollment of patients into this arm was discontinued because of the severity of local skin reactions.

A second randomized open-label trial of the use of imiquimod in nodular BCCs compared a 3 times per week application regimen for 8 weeks versus 12 weeks, with histopathologic assessment at 8 weeks posttreatment. Although an intent-to-treat analysis was not performed, a complete histopathological clearance was observed in 58 of 90 (64%) patients, with no statistically significant difference between the 8-week versus 12-week treatment arms.27

Although imiquimod as a monotherapy for nodular BCCs may not be justified on the basis of current data, imiquimod has shown efficacy as an adjunctive treatment after curettage and electrodesiccation of nodular BCCs. In a double-blind, vehicle-controlled study of 20 patients with nodular BCCs, a substantial decrease in the number of patients with evidence of residual tumor was seen after daily application of imiquimod for 1 month after curettage and electrodesiccation (1/10 with residual tumor in treatment group vs 4/10 with residual tumor in vehicle group).28

Sukal and colleagues29 reported 2 cases of recurrent nodular BCC after reported clinical clearance with imiquimod therapy. They presented intraoperative frozen sections demonstrating recurrent BCC during Mohs microscopic surgery on these prior treated patients. The tumor was mid-dermis with a Grenz zone like clearance of tumor in the superficial dermis and epidermis. This highlights the limitation a topical may have in penetrating deeply to effectively treat the depth of the tumor. They stress the importance of continued clinical as well as histopathological monitoring of patients who undergo treatment of NMSC with topical therapy and suggest limiting treatment with topical therapy of NMSC to superficial primary nonfacial lesions less than 2 cm.

### Imiquimod for Squamous Cell Carcinoma In-Situ

A number of studies have shown efficacy in the treatment of SCCIS with imiquimod, as outlined in Table 2. The authors of a randomized, double-blind, placebo-controlled trial investigating the treatment of biopsy proven SCCIS with daily application of imiquimod for 16 weeks resulted in a 73% (11/15) complete response rate as assessed by histopathologic examination (shave biopsy) at 12 weeks posttreatment.30 Furthermore, in an open-label study by Mackenzie-
Wood et al\textsuperscript{31} in which 16 patients with SCCIS \( \geq 1 \text{ cm} \) in diameter were treated with daily application of imiquimod for 16 weeks, a response rate of 87.5% (14 of 16 patients) was documented at 6 weeks posttreatment through incisional biopsy. Of note, 10 patients completed 16 weeks of treatment while 6 patients terminated treatment early because of local skin reaction, including 4 cases of \textit{Staphylococcus aureus} colonization. Finally, Peris et al\textsuperscript{32} evaluated once daily application of imiquimod for 5 consecutive days a week for up to 16 weeks in 10 patients with 12 cases of squamous cell carcinoma, including 7 invasive SCC lesions, with punch biopsy performed at 4 weeks after treatment discontinuation. In this study, 4 of 5 (80%) patients with SCCIS and 5 of 7 (71.4%) patients with invasive SCCs had complete regression after 8-12 weeks of treatment, with correlation noted between clinical and histopathologic evaluation. No recurrences were noted after a mean follow-up time of 31 months.

**Review of Photodynamic Therapy for Nonmelanoma Skin Cancer**

In 1999, photodynamic therapy was approved for the treatment of nonhyperkeratotic solar keratoses on the face and scalp as a 20% topical 5-aminolaevulinic acid (ALA), Levulan (DUSA Pharmaceuticals, Wilmington, MA), in combination with a blue light source with 417 nm peak output. Several years later, application of MAL, Metvix (PhotoCure ASA, Oslo, Norway; and Galderma, Paris, France) followed by illumination with a red light source with 630 nm peak output was also approved for the treatment of actinic keratoses. These 2 topical photosensitizers are converted to protoporphyrin IX in the membranes of mitochondria and lysosomes, which upon irradiation with visible light in the 450- to 750-nm wavelength range, generates reactive oxygen species with subsequent apoptosis and damage to target cells. Photodynamic therapy has been increasingly used in several dermatologic conditions, of which the data regarding its efficacy in nonmelanoma skin cancer will be critically reviewed below.

In 2007, the International Society for Photodynamic Therapy in Dermatology presented recommendations based on available data at the time of the report. The reported guidelines were made on the quality of clinical trial data, evidence-based results, safety, and tolerability as well as cosmesis and patient satisfaction. The reported guidelines are as follows: Superficial basal cell (including large and multiple lesions) can be effectively and reliably treated with limited side effects and good cosmetic results with PDT. Nodular BCC, of <2 mm in-depth, has been shown in long-term follow up of 5 years to be effectively treated with MAL-PDT with good cosmetic result. SCCIS or Bowen’s disease can also be effectively treated with PDT with good cosmesis.\textsuperscript{33}

**Photodynamic Therapy for Basal Cell Cancer**

In general, cure rates for superficial BCCs have ranged from 62% to 91%, with those for nodular BCCs ranging from 50% to 92%, as summarized in Table 3. This broad range is likely attributable to varied treatment regimens and outcome measures among published studies, thus making meaningful comparisons difficult.

In a prospective, randomized study by Rhodes et al\textsuperscript{34} comparing surgical excision (5 mm margin) of nodular BCC with MAL-PDT (3-hour incubation, red light 570-670 nm, 75 J/cm\(^2\), 20-200 mW/cm\(^2\), 1-2 cycles), the 5-year complete response rate was 76% in the MAL-PDT group versus 96% for those undergoing surgical excision (\(P = 0.01\)). However, MAL-PDT led to a more favorable cosmetic outcome, which was noted to be good or excellent in 27 of 31 (87%) of patients with MAL-PDT versus 19 of 35 patients (54%) treated with excision. The efficacy of ALA-PDT (6-hour incubation, frequency doubled Nd:YAG 635 nm, pulse width 100 ns, 60 J cm\(^{-2}\), 80 \(\pm\) 20 mW cm\(^{-2}\), 1-2 cycles) in the treatment of superficial and nodular BCCs has also been compared with cryosurgery in a prospective randomized trial, with histologic assessment (punch biopsy) at 12 months as the primary end point. They found no statistically significant difference in either treatment modality, with a recurrence rate of 25% (11 of 44) for the ALA-PDT group and 15% (6 of 39) for cryosurgery.

Interestingly, a greater recurrence rate was noted for superficial BCCs (38%, 8/21) compared with nodular BCCs (13%, 3/23).\textsuperscript{35} Conflicting results were noted in an analysis of 2 multicenter, randomized, double-blind controlled trials in which the authors evaluated the efficacy of MAL-PDT (gentle curettage, 3-hour incubation, broadband red light 570-670 nm, 75 J/cm\(^2\), 50-200 mW/cm\(^2\), 2 PDT sessions \(\times 1-2\) cycles) versus vehicle cream in the treatment of nodular BCCs, with histopathologic analysis at 6 months. Although a complete response rate of 73% (53/75) was noted for those undergoing MAL-PDT versus 27% (20/75) in the placebo group, the rate was worse in larger lesions (\(\geq 1\) cm in diameter) and in lesions with a depth of >1 mm.\textsuperscript{36}

Others have also shown that tumor thickness in nodular BCCs correlates with response. Kalka et al found that 67% of nodular BCCs <2 mm in thickness achieved a complete response after PDT, whereas only 34% of thicker tumors responded.\textsuperscript{37} Repeated illumination has also been evaluated in a prospective, randomized, controlled trial in which 149 patients with 173 nodular BCCs either received surgical excision (3 mm margin) versus ALA-PDT (debulking with curettage 3 weeks prior, 4-hour incubation, broadband metal halogen light source 585-720 nm, with repeat illumination after 1 hour). With a median follow-up time of 28 months, 2 recurrences were noted in the excision group versus 21 in the ALA-PDT group, resulting in a failure rate of 2.3% for excision and 30.3% for ALA-PDT.\textsuperscript{38}

The authors of a multicenter randomized study investigating MAL-PDT (3-hour incubation, wavelength 570-670 nm, light dose 75 J/cm, 1-3 cycles) versus cryotherapy in the treatment of superficial BCCs found no statistically significant difference in 5-year recurrence rates (20% with cryotherapy vs 22% with MAL-PDT, \(P = 0.86\)).\textsuperscript{39} An open-label trial examining MAL-PDT (debulking with curettage, 3-hour incubation, red light 634 nm, 2 treatments separated by

---
<table>
<thead>
<tr>
<th>Sample Size</th>
<th>Sensitizer</th>
<th>Incubation Time</th>
<th>Light Source</th>
<th>No. of Treatments</th>
<th>Clearance Rate, %</th>
<th>Follow-Up Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Superficial BCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>MAL-PDT</td>
<td>3 h</td>
<td>Red light 570-670 nm</td>
<td>1-3</td>
<td>78%</td>
<td>5 years</td>
</tr>
<tr>
<td>23</td>
<td>ALA-PDT</td>
<td>6-8 h</td>
<td>630 nm</td>
<td>2</td>
<td>86.9%*</td>
<td>2-3 years</td>
</tr>
<tr>
<td>26</td>
<td>ALA-PDT</td>
<td>3 h of ALA, then 1 h of EMLA cream</td>
<td>630 nm ± 15 nm</td>
<td>2</td>
<td>4%†</td>
<td>15-45 mo</td>
</tr>
<tr>
<td>73</td>
<td>ALA-PDT</td>
<td>6 h</td>
<td>630 nm ± 15 nm</td>
<td>1-3</td>
<td>78-86%</td>
<td>34-41 mo</td>
</tr>
<tr>
<td>131‡</td>
<td>MAL-PDT §</td>
<td>3-24 h</td>
<td>Halogen light 570-670 nm</td>
<td>1-4</td>
<td>91%†</td>
<td>2-4 years</td>
</tr>
<tr>
<td>94</td>
<td>MAL-PDT §</td>
<td>3 h</td>
<td>Red light 634 nm ± 3 nm</td>
<td>Up to 8</td>
<td>87.2%†</td>
<td>1 year</td>
</tr>
<tr>
<td>21</td>
<td>ALA-PDT</td>
<td>6 h</td>
<td>Nd:YAG 635 nm</td>
<td>1-5</td>
<td>62%</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Nodular BCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>ALA-PDT</td>
<td>6-8 h</td>
<td>630 nm</td>
<td>4</td>
<td>50%*</td>
<td>2-3 years</td>
</tr>
<tr>
<td>75</td>
<td>MAL-PDT §</td>
<td>3 h</td>
<td>Red light 570-670 nm</td>
<td>2-4</td>
<td>73%</td>
<td>3-9 mo</td>
</tr>
<tr>
<td>83</td>
<td>ALA-PDT §</td>
<td>4 h</td>
<td>Halogen light 585-720 nm (illuminated twice)</td>
<td>1</td>
<td>69.7%†</td>
<td>28 mo</td>
</tr>
<tr>
<td>168‡</td>
<td>MAL-PDT §</td>
<td>3-24 h</td>
<td>Halogen 570-670 nm</td>
<td>1-4</td>
<td>89%†</td>
<td>2-4 years</td>
</tr>
<tr>
<td>24</td>
<td>MAL-PDT §</td>
<td>3 h</td>
<td>Red light 634 nm ± 3 nm</td>
<td>Up to 8</td>
<td>52.5%†</td>
<td>1 year</td>
</tr>
<tr>
<td>24</td>
<td>ALA-PDT §</td>
<td>6 h</td>
<td>Red light 630-635 nm</td>
<td>1</td>
<td>92%</td>
<td>3 mo</td>
</tr>
<tr>
<td>23</td>
<td>ALA-PDT</td>
<td>6 h</td>
<td>Nd:YAG 635 nm</td>
<td>1-5</td>
<td>87%</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Pigmented BCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>ALA-PDT</td>
<td>6-8 h</td>
<td>630 nm</td>
<td>4</td>
<td>0%*</td>
<td>2-3 years</td>
</tr>
<tr>
<td><strong>Unspecified or multiple BCC types</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>ALA-PDT</td>
<td>6 h</td>
<td>630 nm ± 15 nm</td>
<td>1-3</td>
<td>78-86%</td>
<td>34-41 mo</td>
</tr>
<tr>
<td>350</td>
<td>MAL-PDT</td>
<td>3-24 h</td>
<td>Halogen 570-670 nm</td>
<td>1-4</td>
<td>79%†</td>
<td>2-4 years</td>
</tr>
</tbody>
</table>

ALA-PDT, 5-aminolaevulinic acid photodynamic therapy; BCC, basal cell carcinoma; MAL-PDT, methyl-aminolaevulinate photodynamic therapy.

*Based on histology at 30 days after treatment or clinical examination at 24-36 months.
†Based on clinical examination only, although Soler, et al confirmed clinically suspicious recurrence with cytology.
‡Only including those with complete clinical response at 3-6 months after treatment.
§With tumor or debulking.
1-week up to maximum of 8 monthly sessions) for the treatment of 94 superficial and 24 nodular BCCs, including 25 recurrent BCCs, resulted in complete clinical and histopathological resolution in 84 of 94 (89.4%) superficial BCCs and 12 of 23 (52.2%) nodular BCCs, with no further efficacy gained with repeat treatments. Recurrence was observed in 2 of 84 (2.4%) superficial BCCs at a mean follow-up of 12 months.

Thissen et al,41 also examined debulking with curettage 3 weeks before treatment with ALA-PDT (6-hour incubation, red light 630-635 nm, 120 J/cm², 100 mW/cm²) in 23 patients with 24 nodular BCCs and found that 22 of 24 (92%) nodular BCCs showed a complete response on clinical and histopathological examination at 3 months after treatment, with good or excellent cosmetic results in the 22 resolved BCCs. It is important to note that a study by Barlow, et al documented a 96% cure rate when treating selected basal cell carcinomas with curettage alone (no electrocautery). The utility of MAL-PDT in the prevention and treatment of BCCs in patients with basal cell nevus syndrome has also been demonstrated, representing an attractive treatment modality for early lesions arising in clinically normal skin.

In addition to debulking of the tumor via curettage or repeat PDT treatments, techniques by which to improve the efficacy of PDT for BCCs have included adjunctive laser treatment, penetration enhancers, such as dimethyldisulfoxide (DMSO), and microdermabrasion. Curettage and DMSO treatment (5-min exposure, 99% solution for lesions on trunk and extremities; 4% DMSO added to ALA for lesions on face and scalp) before ALA-PDT of nodular and superficial BCCs (3-hour incubation, broadband light 550-700 nm) resulted in a complete histologic clearance at 3 years’ follow-up in 43 of 53 (81%) treated lesions. A control group was not evaluated.

Soler et al,44 incorporated a 15 minute pretreatment with DMSO before ALA treatment of superficial BCCs (3-hour incubation), and compared the efficacy with exposure to either broadband light (570-740 nm) or laser light (630 nm). A complete clinical response at 6 months was noted in 86% of patients treated with laser light compared with 82% treated with broadband light, although this difference was not statistically significant. It has also been shown that microdermabrasion before PDT treatment results in increased erythema at the treatment site, although its effect on efficacy in the treatment of BCCs has not yet been determined.45 Er:YAG laser treatment (600-1000 mJ, 7 Hz) before MAL-PDT (3-hour incubation, Aktelite 630 nm, 37 J/cm²) for recurrent nodular BCCs of the head and neck led to a clinical resolution in 98.7% of patients undergoing combined Er:YAG/MAL-PDT treatment versus 94.85% in the MAL-PDT only group versus 91.75% in the Er:YAG laser only group. Of note, this analysis was based on only 194 of 286 patients originally treated.46 CO₂ laser (Ultra Pulse CO₂ laser, 150 mJ, 10 Hz, 2-mm collimated beam) followed by MAL-PDT (3-hour incubation, Aktelite LED lamp 631 nm, 37 J/cm², 2 treatments given at a 1-week interval) was performed in 12 patients with 13 nodular BCCs, with all lesions responding clinically and no recurrences detected at a mean follow-up time of 18 months. Two cases of hypopigmentation were reported.

**Photodynamic Therapy for Squamous Cell Cancer In Situ**

Although the efficacy of PDT in the treatment of SCCIS has been demonstrated, recurrence rates are in general higher compared with surgical excision, ranging from 7% to 15% in most published studies. Most studies to date present limited data based on clinical rather than histologic-clearance. A summary of these studies is provided in Table 4.

In a randomized study comparing treatment of SCCIS with ALA-PDT followed by illumination with either red light (4-hour incubation, 630 nm ± 15 nm, 125 J/cm², 86 mW cm²) or green light (4-hour incubation, 540 nm ± 15 nm, 62.5 J/cm², fluence 86 mW cm²), 30 of 32 (94%) lesions treated with red light had clinical clearance after 1 to 2 treatments compared with only 21 of 29 (72%) lesions treated with green light (P = 0.002). At 1-year follow-up, 7 recurrences were noted in patients having received illumination with green light compared with only 2 recurrences in patients treated with red light.48 In an open label trial of 14 patients with 36 lesions of SCCIS treated with ALA-PDT (3- to 6-h incubation 630 nm, 125-250 J/cm², 150 mW/cm²), complete clinical response was seen in 35 of 36 (97%) lesions at 2 months, which decreased to 89% (32 of 36 lesions) at a median follow-up time of 18 months.49 In a retrospective study by Fink-Puches et al,50 35 superficial SCCs were treated with ALA-PDT (4-h incubation, slide projector—full spectrum or filtered visible light, 50-100 mW/cm²). Complete clinical response after 2-4 weeks post-treatment was noted in 19 of 35 cases (54%). In a median follow-up time of 8 months, 11 of 19 patients developed a recurrence of disease, 5 of 19 remained complete responders, and 3 were lost to follow-up. In treating large diameter (>20 mm) plaques of SCCIS with ALA-PDT (4-h incubation, 630 nm ± 15 nm, 125 J/cm², 1-3 treatments), 35 of 40 (88%) lesions had complete clinical clearance 6 weeks posttreatment, of which 4 occurred within 1 year.

In a subanalysis of patients with ≥3 plaques of SCCIS, 44 of 45 (98%) plaques cleared, with 4 recurrences within 1 year.51 Varma et al52 also investigated ALA-PDT (4-h incubation, 630 nm, 105-168 mW/cm², 105 J/cm²) in the treatment of SCCIS and found clinical clearance in 44 of 50 (88%) lesions after 2 treatment sessions, although this abruptly dropped to 69% at 1-year follow-up, with most recurrences occurring within 6 months. An 82% (27/33) clinical clearance rate at 1 year was observed in a study by Salim et al,53 in which 33 lesions of SCCIS were treated with ALA-PDT (4-hour incubation, red light 630 nm ± 15 nm, 100 J/cm², 50-90 mW/cm²). A case report demonstrating efficacy of ALA-PDT (4-hour incubation, red light 635 nm) in the treatment of subungual SCCIS has also been published, with no evidence of clinical recurrence after 30 months.

As mentioned previously in this review, treatment of SCCIS with MAL-PDT (3-hour incubation, red light 570-670 nm, 75 J/cm²) versus cryotherapy or 5-FU in a randomized,
placebo controlled study yielded a complete clinical response 3 months post-treatment in 103 of 111 (93%) patients treated with MAL-PDT versus 73 of 85 (86%) in the cryotherapy group versus 24 of 29 (83%) patients treated with 5-FU. Recurrence rates at 1 year were 15% in MAL-PDT group, versus 21% in the cryotherapy group, versus 17% in 5-FU group.20

Photodynamic Therapy for Invasive Squamous Cell Cancer

There is limited published data at this time to support the implementation of photodynamic therapy as a treatment modality for invasive squamous cell cancer. As with nodular BCCs, the depth of penetration of ALA or MAL as well as limited depth of penetration of illumination sources into tissue may prohibit destruction of these lesions.

In an open label study by Calzavara-Pinton et al which included 6 nodular SCCs treated with ALA-PDT (6- to 8-hour incubation, 630 nm argon-pumped dye laser, 60-80 J/cm², treatments were repeated every other day for 4 treatments), histopathologic resolution was observed in only 2 of 6 (33%) lesions at a median follow-up time of 29 months.54 The noted high recurrence rates and metastatic potential of SCC has limited further investigation to date.

Photodynamic Therapy for Extramammary Paget’s Disease

Much of the data regarding the use of photodynamic therapy for extramammary Paget’s disease is derived from case reports and case series. Mohs micrographic surgery currently produces the lowest recurrence rates compared with standard surgical techniques. In fact, local recurrence is quite common with surgical excision, ranging from 31% to 61% in some studies, thus adjunctive treatments may be needed to control disease.55

A retrospective case series published by Housel et al56 in which 5 patients with 16 lesions of anogenital extramammary Paget’s disease who were treated with ALA-PDT (18-24-h incubation, red light 632 nm), with use of adjuvant iontophoresis and fractionated light delivery through use of a red lamp (590-720 nm). At 6 months' follow-up, 8 of 16 (50%) lesions demonstrated a complete response, 3 of 16 (19%) lesions had a partial response, and 5 of 16 (31%) lesions had a marginal response. Three lesions that initially had a complete response developed recurrences within 10 months. Included in this study were also patients treated with intravenous porfimer sodium PDT, which resulted in clinical clearance in 7 of 9 lesions at a median follow-up time of 29 months.54 The noted high recurrence rates and metastatic potential of SCC has limited further investigation to date.

A second series by Raspagliesi et al57 in which 7 patients with recurrent vulvar extramammary Paget’s disease underwent MAL-PDT (3-hour incubation, Aktlite red light 620 nm, 37 J/cm², treatment every 3 weeks for 3 treatments) found a clinical complete response in 4 of 7 patients, although this was confirmed histologically in only 2 patients.

Table 4 Select Studies Addressing PDT for SCC48-52,54

<table>
<thead>
<tr>
<th>Sample Size</th>
<th>Sensitizer</th>
<th>Incubation Time, h</th>
<th>Light Source</th>
<th>No. of Treatments</th>
<th>Clearance Rate*</th>
<th>Follow-Up Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCC in situ</td>
<td>ALA-PDT</td>
<td>2.4</td>
<td>630 nm</td>
<td>1</td>
<td>89%</td>
<td>18 mo</td>
</tr>
<tr>
<td>Calzavara-Pinton et al</td>
<td>ALA-PDT</td>
<td>6-8</td>
<td>630 nm</td>
<td>35</td>
<td>100%†</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Morton et al</td>
<td>ALA-PDT</td>
<td>4</td>
<td>Lamp</td>
<td>1</td>
<td>0.88</td>
<td>8 mo</td>
</tr>
<tr>
<td>Varma et al</td>
<td>ALA-PDT</td>
<td>4</td>
<td>Red light 630 ± 15 nm</td>
<td>4</td>
<td>0.48</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Morton et al</td>
<td>ALA-PDT</td>
<td>4</td>
<td>Green light 540 ± 15 nm</td>
<td>4</td>
<td>0.88</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Calzavara-Pinton et al</td>
<td>ALA-PDT</td>
<td>4</td>
<td>Waldmann PDT 1200-630 nm</td>
<td>1</td>
<td>0.88</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Calzavara-Pinton et al</td>
<td>ALA-PDT</td>
<td>6-8</td>
<td>630 nm</td>
<td>2</td>
<td>100%†</td>
<td>2-3 years</td>
</tr>
<tr>
<td>Calzavara-Pinton et al</td>
<td>ALA-PDT</td>
<td>6-8</td>
<td>630 nm</td>
<td>2</td>
<td>100%†</td>
<td>2-3 years</td>
</tr>
</tbody>
</table>

* Based on clinical examination.† Based either on histological examination at 30 days after treatment or clinical examination at 24-36 months.
Intralesional Photodynamic Therapy for Nonmelanoma Skin Cancer

It has been postulated that insufficient penetration of ALA may account for the lower efficacy rates encountered in nodular BCCs undergoing PDT treatment. Intralesional injection of ALA rather than topical application has been suggested as a means to increase tumor response to this treatment modality. In support of this, intracutaneous injection of ALA has demonstrated a greater level of protoporphyrin IX fluorescence in porcine skin compared with topical application. Furthermore, de Blois et al have developed a stable composition of ALA (concentration of 0.1-5.0% and a pH of 5.0) that they conclude would be suitable for intratumoral injection.

A current study by the authors of this review paper addresses the effectiveness of non-coherent blue light in intralesional PDT for the treatment of BCC. A prospective study of 20 BCCs treated with injection of 20% aminolevulinic acid, incubated for 1 hour, and exposed to noncoherent blue light has been initiated. When clinical clearance was not achieved at 8 weeks, the BCC was treated a second time. Evaluations at 16 weeks, 1 year, and 2 years after PDT include punch biopsies of the treatment sites. To date, all 20 BCCs have been evaluated at 16 weeks, showing recurrence at 2 sites on histology. For those 18 sites still negative at 16 weeks, 13 have been reevaluated at 1 year, revealing an additional 4 sites of histologic recurrence. Five have returned for their 2 year examination and shown recurrence at 1 more site. An example of a complete clinical clearance at the 2-year follow-up visit is demonstrated in Fig. 1. Although the recurrence rate may increase with the pending 1 and 2 year follow-up visits, the overall recurrence rate, including non-responders, is presently 35% (7 of 20 sites). Notably, physicians graded cosmetic outcome as good-to-excellent in 2/3 or more of the treatment sites at all follow-up examinations. No unusual adverse event has been appreciated.

Adverse Effects of Photodynamic Therapy

During exposure of the photosensitizer to light, pain, burning, and/or pruritus have been noted, with peak effects usually experienced within the first few minutes of treatment. It has been hypothesized that these local skin reactions are secondary to nerve stimulation and/or tissue damage by reactive oxygen species. A number of studies have shown that pain is greater using ALA compared with MAL, possibly reflecting greater protoporphyrin IX fluorescence. Although analgesia is not typically required, one could consider pretreatment with topical lidocaine and Prilocaine (EMLA; AstraZeneca, Luton, UK) or the use of cooling fans/sprays during treatment. After exposure to light, photosensitivity continues to increase, thus patients should strictly avoid exposure to light for at least 48 hours to prevent phototoxic reactions. Edema and erythema can also occur, with the potential for crusting and erosions. Complete healing can be expected within 1-6 weeks. Although the incidence of scarring is rare, pigmentary alteration has been noted in 1% of patients. Most cases of postinflammatory hypo- or hyperpigmentation resolve within a few months.

Other Nonsurgical Treatment Modalities for Nonmelanoma Skin Cancer

Peels

Phenol peels have also been examined in the treatment of SCCIS. Kaminaka et al, in a study in which 14 patients with SCCIS underwent treatment with phenol peels, found 10 of 14 patients experienced a complete clinical and histopathologic response, with only 1 case recurring in 1-year follow-up.
Lasers

A number of case reports have been published documenting efficacy of CO2 laser treatment of both BCC and SCCIS. One of the earlier reports examining efficacy of CO2 laser for treatment of NSMC was Humphreys et al. They histologically examined 30 superficial NSMCs (17 BCCs, 13 SCC) treated with pulsed CO2 laser (500 mJ, 3-mm spot size, 30 Hz, 3-mm spot size, 3 to 4 passes) with confirmation demonstrated by Mohs micrographic surgery of a representative lesion, with no recurrences at 18-months follow-up. Iyer et al. examined treatment of 61 biopsy proven superficial and nodular BCCs treated with a pulsed CO2 laser (pulse energy of 300-500 mJ, spot size 3 mm, 10 Hz, 2-8 passes). Patients were followed from 15 to 85 months with clinical recurrence noted in only 2 cases. They report anecdotally favorable cosmetic outcomes. Horlock, et al histologically examined effects of CO2 laser of 51 BCCs, including superficial, nodular and infiltrative, and documented a 100% cure rate for all superficial BCCs. They note this occurred when ablation to middermis was achieved. In a small case series of 3 lesions of SSCIS, CO2 laser treatment (500 mJ, 3-mm spot size) followed by diode laser treatment (60 J/cm2, 9 mm x 9 mm spot size, 30 ms pulse duration) resulted in clinical clearance of all lesions with a 4-month follow-up time. The fairly favorable documented clearance rates and ability to limit peripheral tissue damage with small spot size and pulse energy makes this a reasonable treatment modality.

More recently, pulsed dye laser has been evaluated for efficacy in the treatment of BCC. Shah and colleagues theorize that dependency of tumor growth on stromal tissue and vascularity explains the reduction in tumor growth with this treatment option. The trial of pulsed dye laser (15 J/cm2, 3-5 ms pulse duration, 7-mm spot size, 4 treatments every 2-4 weeks) on biopsy-proven BCC showed that 11 of 12 BCCs, 1.5 cm or less in size, had complete histologic clearance.

Wasserman and colleagues presented the treatment of 13 BCCs (with long pulsed alexandrite laser: 3-ms pulse duration, 8-mm spot size, 100 J/cm2), of which 10 underwent a single treatment and 3 underwent 4 treatments. Of those undergoing 4 treatments, all 3 lesions showed complete histologic clearance. Of the 10 lesions undergoing 1 treatment, 4 had complete histologic clearance. Although both pulsed-dye (595 nm) and alexandrite (755 nm) lasers may be preferentially absorbed by vascular structures, the extremely high settings used in both the Tannous and the Wasserman studies create an ablative like tissue response which may play a significant role in the noted tumor clearance.

Conclusions

Millions of NMSCs are treated in the United States annually. An urgent need for alternative and preventive treatments is needed, especially for those patients who are poor surgical candidates or those prone to numerous NMSCs. Although not as efficacious as Mohs micrographic surgery, alternative strategies may be well suited in some instances. Various degrees of efficacy have been found with topical retinoids, 5-FU, imiquimod, photodynamic therapy, chemical peels, and a variety of lasers. The future will likely bring optimized treatment regimens and new technologies that may further improve the success rate against these cancers.

References

Do lasers or topicals really work for NMSCs?


